跳至主要内容
临床试验/NCT00625872
NCT00625872终止3 期

Neuromuscular Changes In Small For Gestational Age (SGA) Children During Somatropin Therapy - A Prospective Randomized, Controlled, Open-Label Multicenter Trial

Pfizer1 个研究点 分布在 1 个国家目标入组 23 人开始时间: 2008年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
终止
发起方
Pfizer
入组人数
23
试验地点
1
主要终点
Change From Baseline in Maximum Jump Velocity (Vmax; Two-leg-jump) in Per Protocol (PP) Population at Month 6

研究概览

简要总结

The planned study focuses on the effect of a one year Somatropin treatment (0.035 mg/kg/d or 0.067 mg/kg/d) in short children born SGA on neuromuscular function and cognitive performance.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
6 Years 至 10 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Pre-pubertal boys between 6 and 10 years of age or girls between 6 and 9 years of age.
  • Birth length- and/or birth weight-SDS adjusted to gestational age < -2.0 (Voigt et al. 2002, Voigt et al. 2006 or Lawrence et al. 1989).
  • Current height-SDS < -2.5 (Brandt/Reinken 1992) and parental adjusted height-SDS below -1 (Hermanussen and Cole 2003).
  • Growth velocity SDS < 0 during the last year before inclusion (Brandt/Reinken 1988).

排除标准

  • Severe SGA (birth weight or length < -4 SD) and clinically relevant dysmorphic features.
  • Severe pre-maturity (GA < 32 weeks of gestation).
  • Severe perinatal complications like asphyxia, sepsis, necrotizing enterocolitis (NEC), respiratory distress syndrome, if associated with long-term sequelae (like short bowel syndrome, bronchopulmonary dysplasia (BPD), cerebral palsy etc).
  • Inability to perform one- or two leg jumps from a standing position.
  • Prior GH treatment.

研究组 & 干预措施

Treatment Group

Active Comparator

Somatropin for 12 months

干预措施: Somatropin (Drug)

Control Group

Other

In the first 6 months no intervention, afterwards Somatropin for 12 months

干预措施: Somatropin (Drug)

结局指标

主要结局

Change From Baseline in Maximum Jump Velocity (Vmax; Two-leg-jump) in Per Protocol (PP) Population at Month 6

时间窗: Baseline and Month 6

Vmax was measured by Leonardo Jumping Platform during two-leg jump.

Change From Baseline in Peak Jump Power Standard Deviation Score (PJP-SDS; Two-leg-jump) in Full Analysis Set (FAS) Population at Month 6

时间窗: Baseline and Month 6

Peak jump power (PJP) was defined as the peak of the calculated power (force multiplied by velocity). It was measured by Leonardo Jumping Platform during two-leg jump. The participant performs 3 jumps and the highest peak (PJP) of the 3 recordings was selected for further calculations. The SDS indicates how similar the participant was to the reference population.

Change From Baseline in Peak Jump Force Standard Deviation Score (PJF-SDS; Two-leg-jump) in Per Protocol (PP) Population at Month 6

时间窗: Baseline and Month 6

PJF was defined as the maximum of force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms and as high as possible with the head and chest. It was measured by Leonardo Jumping Platform during two-leg jump. The SDS indicates how similar the participant was to the reference population.

Change From Baseline in Peak Jump Power Standard Deviation Score (PJP-SDS; Two-leg-jump) in Per Protocol (PP) Population at Month 6

时间窗: Baseline and Month 6

PJP was defined as the peak of the calculated power (force multiplied by velocity). It was measured by Leonardo Jumping Platform during two-leg jump. The participant performs 3 jumps and the highest peak (PJP) of the 3 recordings was selected for further calculations. The SDS indicates how similar the participant was to the reference population.

Change From Baseline in Maximum Jump Velocity (Vmax; Two-leg-jump) in Full Analysis Set (FAS) Population at Month 6

时间窗: Baseline and Month 6

Vmax was measured by Leonardo Jumping Platform during two-leg jump.

Change From Baseline in Peak Jump Force Standard Deviation Score (PJF-SDS; Two-leg-jump) in Full Analysis Set (FAS) Population at Month 6

时间窗: Baseline and Month 6

PJF was defined as the maximum of force of the ascending part of the jump which the participant performed as a counter-movement jump with freely moving arms and as high as possible with the head and chest. It was measured by Leonardo Jumping Platform during two-leg jump. The SDS indicates how similar the participant was to the reference population.

次要结局

  • Change From Baseline in Intellectual Performance of Children Using Kinderversion Der Testbatterie Zur Aufmerksamkeitsprüfung für Kinder (KITAP) Test at Month 6(Baseline and Month 6)
  • Change From Baseline in Peak Jump Power Standard Deviation Score (PJP-SDS; One-leg-jump) at Months 6, 12 and 18(Baseline, Month 6 , Month 12 and Month 18)
  • Change From Baseline in Peak Jump Force Standard Deviation Score (PJF-SDS; One-leg-jump) at Months 6, 12 and 18(Baseline, Month 6, Month 12 and Month 18)
  • Change From Baseline in Five-chair Rising Test- Peak Jump Power (PJP) at Month 6(Baseline and Month 6)
  • Change From Baseline in Five-chair Rising Test-Peak Jump Force (PJF) at Months 12 and 18(Baseline, Month 12 and Month 18)
  • Change From Baseline in Intellectual Performance of Children Using Kaufmann-Assessment Battery for Children (K-ABC) Test Global Scales at Months 12 and 18(Baseline, Month 12 and Month 18)
  • Change From Baseline in Intellectual Performance of Children Using Child Behavior Checklist 4-18 Years (CBCL 4-18) at Months 6, 12 and 18(Baseline, Month 6, Month 12 and Month 18)
  • Change From Baseline in Five-chair Rising Test-Peak Jump Power (PJP) at Months 12 and 18(Baseline, Month 12 and Month 18)
  • Change From Baseline in Five-chair Rising Test-Peak Jump Force (PJF) at Month 6(Baseline and Month 6)
  • Change From Baseline in One-chair Rising Test-Peak Jump Power (PJP) at Months 6, 12 and 18(Baseline, Month 6 , Month 12 and Month 18)
  • Mean Thigh Circumference(Baseline, Month 6, Month 12 and Month 18)
  • Mean Height at Month 6(Month 6)
  • Change From Baseline in Intellectual Performance of Children Using Non-verbal Learning Test (NVLT) at Months 12 and 18(Baseline, Month 12 and Month 18)
  • Change From Baseline in Maximum Jump Velocity (Vmax; One-leg-jump) at Months 6, 12 and 18(Baseline, Month 6, Month 12 and Month 18)
  • Mean Growth Velocity at Months 12 and 18(Month 12 and Month 18)
  • Mean Height-Standard Deviation Score (SDS) at Month 6(Month 6)
  • Change From Baseline in Intellectual Performance of Children Using Kaufmann-Assessment Battery for Children (K-ABC) Test Global Scales at Month 6(Baseline and Month 6)
  • Change From Baseline in Intellectual Performance of Children Using Non-verbal Learning Test (NVLT) at Month 6(Baseline and Month 6)
  • Change From Baseline in Five-chair Rising Test-Maximum Jump Velocity (Vmax) at Month 6(Baseline and Month 6)
  • Change From Baseline in Five-chair Rising Test (Time to Perform the Tasks) at Months 12 and 18(Baseline, Month 12 and Month 18)
  • Change From Baseline in One-chair Rising Test-Peak Jump Force (PJF) at Months 6, 12 and 18(Baseline, Month 6 , Month 12 and Month 18)
  • Mean Growth Velocity at Month 6(Month 6)
  • Mean Growth Velocity-Standard Deviation Score (SDS) at Month 6(Month 6)
  • Mean Growth Velocity-Standard Deviation Score (SDS) at Months 12 and 18(Month 12 and Month 18)
  • Change From Baseline in Intellectual Performance of Children Using Kinderversion Der Testbatterie Zur Aufmerksamkeitsprüfung für Kinder (KITAP) Test at Months 12 and 18(Baseline, Month 12 and Month 18)
  • Change From Baseline in Five-chair Rising Test-Maximum Jump Velocity (Vmax) at Months 12 and 18(Baseline, Month 12 and Month 18)
  • Change From Baseline in Five-chair Rising Test (Time to Perform the Tasks) at Month 6(Baseline and Month 6)
  • Change From Baseline in Maximal Isometric Grip Force-Standard Deviation Score (MIGF-SDS) at Month 6(Baseline and Month 6)
  • Mean Calf Circumference(Baseline, Month 6, Month 12 and Month 18)
  • Mean Height at Months 12 and 18(Month 12 and Month 18)
  • Change From Baseline in Skinfold Thickness-Standard Deviation Score (SDS) at Month 6(Baseline and Month 6)
  • Mean Height-Standard Deviation Score (SDS) at Months 12 and 18(Month 12 and Month 18)
  • Change From Baseline in One-chair Rising Test (Time to Perform the Tasks) at Months 6, 12 and 18(Baseline, Month 6 , Month 12 and Month 18)
  • Change From Baseline in Maximal Isometric Grip Force-Standard Deviation Score (MIGF-SDS) at Months 12 and 18(Baseline, Month 12 and Month 18)
  • Mean Upper Arm Circumference(Baseline, Month 6, Month 12 and Month 18)
  • Change From Baseline in Growth Velocity-Standard Deviation Score (SDS) at Month 6(Baseline and Month 6)
  • Change From Baseline in Head Circumference-Standard Deviation Score (SDS) at Months 6, 12 and 18(Baseline, Month 6, Month 12 and Month 18)
  • Change From Baseline in Height-Standard Deviation Score (SDS) at Months 12 and 18(Baseline, Month 12 and Month 18)
  • Change From Baseline in Height-Standard Deviation Score (SDS) at Month 6(Baseline and Month 6)
  • Change From Baseline in Growth Velocity-Standard Deviation Score (SDS) at Months 12 and 18(Baseline, Month 12 and Month 18)
  • Sitting Height-Standard Deviation Score (SDS)(Baseline, Month 6, Month 12 and Month 18)
  • Change From Baseline in Head Circumference at Months 6, 12 and 18(Baseline, Month 6, Month 12 and Month 18)
  • Change From Baseline in Skinfold Thickness-Standard Deviation Score (SDS) at Months 12 and 18(Baseline, Month 12 and Month 18)
  • Body Mass Index-Standard Deviation Score (BMI-SDS)(Baseline, Month 6, Month 12 and Month 18)

研究者

发起方
Pfizer
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验